GNRH1 and familial hypercholesterolemia: For example, AI algorithms may advise and remind clinicians to avoid molecules which have a greater effect on bone mass density (BMD) (dienogest monotherapies, GnRH analogues) in younger women; those with greater androgenic effects (NETA) in women with hyperlipidemia, hypercholesterolemia, or signs of hyperandrogenism; and those associated with a higher risk of thromboembolic events (COCs containing third- and fourth-generation progestins, COCs with ≥ 30 mcg ethinyl estradiol, transdermal patches, vaginal rings) in women with known risk factors.